Dosering av protonpumpehemmere

Tidsskrift for den Norske Laegeforening

Volumn 126, Issue 18, 2006, Pages 2397-2399

  Brørs, Odd ^a  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

2 [[(2 PYRIDYL)METHYL]SULFINYL]BENZIMIDAZOLE DERIVATIVE; ANTACID AGENT; ANTIULCER AGENT; BENZIMIDAZOLE DERIVATIVE; CYP2C19 PROTEIN, HUMAN; DRUG DERIVATIVE; ENZYME INHIBITOR; HYDROGEN POTASSIUM ADENOSINE TRIPHOSPHATASE; LANSOPRAZOLE; MIXED FUNCTION OXIDASE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP; SULFOXIDE; UNSPECIFIC MONOOXYGENASE;

DRUG ANTAGONISM; GASTROESOPHAGEAL REFLUX; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; HUMAN; PHARMACOGENETICS; REVIEW;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ANTACIDS; ANTI-ULCER AGENTS; ARYL HYDROCARBON HYDROXYLASES; BENZIMIDAZOLES; ENZYME INHIBITORS; GASTROESOPHAGEAL REFLUX; GENOTYPE; H(+)-K(+)-EXCHANGING ATPASE; HUMANS; MIXED FUNCTION OXYGENASES; OMEPRAZOLE; PHARMACOGENETICS; POLYMORPHISM, GENETIC; PROTON PUMPS; SULFOXIDES;

EID: 33749063464     PISSN: 00292001     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (22)

1. Legemiddelforbruket i Norge 2000-2004. Oslo: Nasjonalt folkehelseinstitutt, 2005.
2. Waldum HL, Fossmark R, Bakke I et al. Hypergastrinemia in animals and man: causes and consequences. Scand J Gastroenterol 2004; 39: 505-9.
3. Fossmark R, Johnsen G, Johanessen E et al. Rebound acid hypersecretion after long-term inhibition of gastric acid secretion. Aliment Pharmacol Ther 2005; 21: 149-54.
4. Caro JJ, Salas M, Ward A. Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials. Clin Ther 2001; 23: 998-1017.
5. Edwards SJ, Lind T, Lundell L. Systematic review of proton pump inhibitors for the acute treatment of reflux oesophagitis. Aliment Pharmacol Ther 2001;15: 1729-36.
6. Castell DO, Kahrilas PJ, Richter JE et al. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol 2002; 97: 575-83.
7. Armstrong D. Review article: gastric pH - the most relevant predictor of benefit in reflux disease? Aliment Pharmacol Ther 2004; 20 (suppl 5): 19-26.
8. Rohss K, Lind T, Wilder-Smith C. Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms. Eur J Clin Pharmacol 2004; 60: 531-9.
9. Aynacioglu AS, Sachse C, Bozkurt A et al. Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population. Clin Pharmacol Ther 1999; 66: 185-92.
10. de Morais SM, Wilkinson GR, Blaisdell J et al. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994; 269: 15419-22.
11. Shirai N, Furuta T, Moriyama Y et al. Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH. Aliment Pharmacol Ther 2001; 15: 1929-37.
12. Andersson T, Hassan-Alin M, Hasselgren G et al. Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole. Clin Pharmacokinet 2001; 40: 411-26.
13. Andersson T, Rohss K, Bredberg E et al. Pharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole. Aliment Pharmacol Ther 2001;15: 1563-9.
14. Kim KA, Shon JH, Park JY et al. Enantioselective disposition of lansoprazole in extensive and poor metabolizers of CYP2C19. Clin Pharmacol Ther 2002;72: 90-9.
15. Tanaka M, Ohkubo T, Otani K et al. Stereoselective pharmacokinetics of pantoprazole, a proton pump inhibitor, in extensive and poor metabolizers of S-mephenytoin. Clin Pharmacol Ther 2001; 69: 108-13.
16. El Omar EM, Oien K, Murray LS et al. Increased prevalence of precancerous changes in relatives of gastric cancer patients: critical role of H. pylori. Gastroenterology 2000; 118: 22-30.
17. Todd JA, Johnston DA, Dillon JF. The changing spectrum of gastroesophageal reflux disease. Eur J Cancer Prev 2002; 11: 215-9.
18. Ruscin JM, Page RL, Valuck RJ. Vitamin B(12) deficiency associated with histamine(2)-receptor antagonists and a proton-pump inhibitor. Ann Pharmacother 2002; 36: 812-6.
19. Viste A, Ovrebo K, Maartmann-Moe H et al. Lanzoprazole promotes gastric carcinogenesis in rats with duodenogastric reflux. Gastric Cancer 2004; 7: 31-5.
20. Qvigstad G, Arnestad JS, Brenna E et al. Treatment with proton pump inhibitors induces tolerance to histamine-2 receptor antagonists in Helicobacter pylori-negative patients. Scand J Gastroenterol 1998; 33: 1244-8.
21. Kleveland O, Syversen U, Slordahl K et al. Hypergastrinemia as a cause of chromogranin a increase in blood in patients suspected to have neuroendocrine tumor. Digestion 2001; 64: 71-4.
22. Orr WC. Sleep and gastroesophageal reflux disease: a wake-up call. Rev Gastroenterol Disord 2004; 4 (suppl 4): S25-32.